Dalacin C phosphate
Country of origin: United States of America, Upjohn Indonesia, Upjohn Belgium, Pharmacy N.V./S.A. Belgium, Eczacibasi Türkiye
Pharm-Group: Antibiotics of the lincomycin group
Manufacturers: Upjohn (United States of America), Upjohn (Indonesia), Upjohn (Belgium), Pharmacia N.V./S.A. (Belgium), Eczacibasi (Türkiye)
International name: Clindamycin
Synonyms: Dalatsin, Dalatsin T, Dalatsin C, Klimitsin, Klimitsin T, Clindamycin, Klindafer, Klindacin, Klinoxin
Dosage forms: solution for injection 150mg/ml, solution for injection 600mg/4ml, solution for injection 300mg/2ml
Composition: Active ingredient - clindamycin.
Indications for use: Infections of the upper and lower respiratory tract (pharyngitis, tonsillitis, scarlet fever, diphtheria, sinusitis, otitis media, pneumonia, including aspiration, lung abscess, bronchitis), abdominal cavity (peritonitis, abscess), oral cavity, urogenital zones (chlamydia, endometritis, vaginal infections, tubo-ovarian inflammation), skin and soft tissues (infected wounds, abscesses), acute and chronic osteomyelitis, septicemia, bacterial endocarditis, acne (externally).
Contraindications: Hypersensitivity, myasthenia gravis, lactation. Restrictions on use: Severe liver and kidney dysfunction, infancy (up to 1 month), pregnancy.
Side effects: Dyspepsia (abdominal pain, nausea, vomiting, diarrhea), esophagitis, liver dysfunction, jaundice, dysbacteriosis (clostridial pseudomembranous colitis), allergic reactions (urticaria, erythema), leukopenia, neutropenia, eosinophilia, thrombocytopenia, hyperbilirubinemia. At the injection site there is irritation, pain, infiltrates and abscesses, thrombophlebitis. With rapid intravenous administration - cardiovascular failure (collapse, cardiac arrest), arterial hypotension.
Interaction: Incompatible with erythromycin, ampicillin, diphenylhydantoin, barbiturates, aminophylline, calcium gluconate and magnesium sulfate. Strengthens (mutually) the effect of rifampicin, aminoglycosides - streptomycin, gentamicin. Deepens muscle relaxation caused by n-cholinergic blockers. Co-administration with antidiarrheal drugs increases the risk of developing pseudomembranous colitis. Concomitant use with solutions containing B complex vitamins is not recommended.
Overdose: No data available.
Special instructions: No data available.
Literature: Encyclopedia of Medicines 2002